<DOC>
	<DOCNO>NCT00153595</DOCNO>
	<brief_summary>The aim double-blind , randomize , parallel group , placebo-controlled study ass efficacy safety EWO1 patient moderate severe perennial allergic rhinitis ( AR ) .</brief_summary>
	<brief_title>EWO1 Persistent Allergic Rhinitis Patients</brief_title>
	<detailed_description>Allergic rhinitis common medical problem affect adult child alike . It estimate 20 % 25 % world ’ population suffer allergic rhinitis , result considerable morbidity - impaired quality life . In U.S. , estimate $ 2.4 billion annual medical cost associate allergic rhinitis . In Taiwan , household dust mite ( HDM ) primary allergen cause allergic reaction include allergic rhinitis . The incidence HDM Taiwan high 100 % . Df , Dp Blomia tropicalis ( Bt ) rank among top 3 common household dust mite . Antihistamines remain major therapy treatment allergic rhinitis . Chinese herb long used treat different allergic immunologic disease . YU-PING-FENG-SAN ( YPFS ) formulation contain 3 herb [ Huangqi ( HQ ) , baizhu ( BZ ) , fangfeng ( FF ) ] report one effective traditional Chinese medicine treatment recurrent rhinitis . In 3 previous non-placebo control clinical study perennial rhinitis , demonstrate add Xingyi ( XY ) YPFS formula CQ , BZ , FF , additional efficacy benefit obtain . The aim double-blind , randomize , parallel group , placebo-controlled study ass efficacy safety EWO1 patient moderate severe perennial allergic rhinitis . After 2-week placebo run-in period , patient satisfy inclusion/exclusion criterion randomize 1:1 receive either EWO1 , placebo 28 day . After treatment-period , patient follow 14 day see rebound rhinitis symptom . The Primary efficacy endpoint weekly combine symptom score end treatment . Besides , intent treat analysis carry efficacy safety . A minimum 60 patient randomized two-treatment parallel-design study .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>1 . Male female patient , age 12 year 2 . AR confirm positive allergen ( dust mite ; Dp ) specific IgE ≧ 2+ within 12 month enrollment 3 . History persistent moderate severe allergic rhinitis 4 . One following : abnormal sleep ; impairment daily activity , sport , leisure ; problem cause work school ; and/or troublesome symptom . 5 . Total nasal symptom score ( nasal rhinorrhea , nasal congestion , nasal itching , sneeze postnasal drip ) ≧ 5 baseline period ( scale 0 : none ; 1 : mild ; 2 : moderate ; 3 : severe ) 6 . No initiation immunotherapy within 6 month dose change immunotherapy 1 month 7 . Signed informed consent obtain prior inclusion study 1 . History recent ( within 6 month ) asthma 2 . Chronic intermittent use inhale , oral , intramuscular ( i.m . ) , intravenous ( i.v . ) , and/or potent/superpotent topical steroid within 2 week 3 . Use prohibit medicine within 2 week 4 . Use longacting antihistamine within 2 week 5 . Documented evidence acute significant chronic sinusitis 6 . Chronic use concomitant medication could interfere assessment 7 . Known suspected hypersensitivity herbal component EWO1 8 . Rhinitis medicamentosa 9 . Planned travel outside study area substantial portion time study 10 . Use another investigational product within past 30 day 11 . Pregnant lactating woman ; woman childbearing potential must use adequate contraception . 12 . Renal dysfunction evidence creatinine level 1.5 x upper limit normal ( ULN ) 13 . Liver dysfunction evidence SGPT &gt; 1.5 x ULN 14 . Signs symptoms upper respiratory infection ( URI ) upon admission</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>EWO1</keyword>
</DOC>